Nasdaq: MYGN

Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium, Showcasing Advances in Breast Cancer Risk Assessment and Treatment

Myriad Genetics Hires Five Senior Executives to Advance Business Growth Plans

New leaders to elevate product portfolio, customer-centric business capabilities, and sales and marketing execution SALT LAKE CITY, Dec. 19 10, 2022 (GLOBE NEWSWIRE) — Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the arrival of five senior executives to help further strengthen the company product roadmap and improve …

Myriad Genetics Hires Five Senior Executives to Advance Business Growth Plans Read More »

Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium, Showcasing Advances in Breast Cancer Risk Assessment and Treatment

Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium, Showcasing Advances in Breast Cancer Risk Assessment and Treatment

A featured discussion sheds light on how the Combined Risk Score can lead to better breast cancer prevention and screening strategies. SALT LAKE CITY, Nov. 29, 2022 (GLOBE NEWSWIRE) — Myriad Genetics, Inc.., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced several new data presentations at the San Antonio Breast Cancer …

Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium, Showcasing Advances in Breast Cancer Risk Assessment and Treatment Read More »